Literature DB >> 28122946

Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults.

Kristen L Nowak1, Traci M Bartz2, Lorien Dalrymple3, Ian H de Boer4, Bryan Kestenbaum4, Michael G Shlipak5,6,7, Pranav S Garimella8, Joachim H Ix9,10,11, Michel Chonchol12.   

Abstract

Within monocytes, 1,25-dihydroxyvitamin D [1,25(OH)2D] is important for production of cathelicidins, which in turn, are critical for antibacterial action. Fibroblast growth factor 23 (FGF23) decreases 1,25(OH)2D production and thus, could increase infection risk. We examined this possibility in 3141 community-dwelling adults ages ≥65 years old at baseline in the Cardiovascular Health Study using Cox proportional hazards models to examine the association between FGF23 concentrations and first infection-related hospitalizations and determine whether associations differed by the presence of CKD (eGFR<60 ml/min per 1.73 m2 [n=832] or urine albumin-to-creatinine ratio >30 mg/g [n=577]). Mean±SD age of participants was 78±5 years old, 60% of participants were women, and the median plasma FGF23 concentration was 70 (interquartile range, 53-99) relative units per milliliter. In fully adjusted models, higher FGF23 concentrations associated with higher risk of first infection-related hospitalization (hazard ratio [HR], 1.11; 95% confidence interval [95% CI], 1.03 to 1.20 per doubling of FGF23) during a median follow-up of 8.6 years. In participants with or without CKD (defined by eGFR), FGF23 concentration associated with first infection-related hospitalization with HRs of 1.24 (95% CI, 1.08 to 1.42) and 1.06 (95% CI, 0.97 to 1.17) per doubling of FGF23, respectively (P=0.13 for interaction). Associations did not differ between groups when stratified by urine albumin-to-creatinine ratio. In sensitivity analyses, the addition of serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did not meaningfully change the estimates. In conclusion, in community-dwelling older adults, higher plasma FGF23 concentrations independently associated with the risk of first infection-related hospitalization.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  aging; chronic kidney disease; clinical epidemiology; infection; mineral metabolism

Mesh:

Substances:

Year:  2016        PMID: 28122946      PMCID: PMC5373449          DOI: 10.1681/ASN.2016040401

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

1.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

Review 2.  Infectious complications in chronic kidney disease.

Authors:  Sakina B Naqvi; Allan J Collins
Journal:  Adv Chronic Kidney Dis       Date:  2006-07       Impact factor: 3.620

3.  Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Authors:  Anna Jovanovich; Joachim H Ix; John Gottdiener; Kim McFann; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Mark Sarnak; Michael G Shlipak; Kenneth J Mukamal; David Siscovick; Michel Chonchol
Journal:  Atherosclerosis       Date:  2013-09-13       Impact factor: 5.162

4.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

5.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.

Authors:  Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2011-09-07       Impact factor: 10.121

6.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

7.  Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey.

Authors:  Adit A Ginde; Jonathan M Mansbach; Carlos A Camargo
Journal:  Arch Intern Med       Date:  2009-02-23

8.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

Authors:  Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

Review 9.  Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Authors:  Justine Bacchetta; Isidro B Salusky; Martin Hewison
Journal:  Pediatr Nephrol       Date:  2012-11-02       Impact factor: 3.714

10.  Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials.

Authors:  Ian H de Boer; Michael C Sachs; Michel Chonchol; Jonathan Himmelfarb; Andrew N Hoofnagle; Joachim H Ix; Robin A Kremsdorf; Yvonne S Lin; Rajnish Mehrotra; Cassianne Robinson-Cohen; David S Siscovick; Michael W Steffes; Kenneth E Thummel; Russell P Tracy; Zhican Wang; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2014-04-03       Impact factor: 8.860

View more
  14 in total

1.  Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Junichi Ishigami; Jonathan T Taliercio; Harold I Feldman; Anand Srivastava; Raymond R Townsend; Debbie L Cohen; Edward J Horwitz; Panduranga Rao; Jeanne Charleston; Jeffrey C Fink; Ana C Ricardo; James Sondheimer; Teresa K Chen; Myles Wolf; Tamara Isakova; Lawrence J Appel; Kunihiro Matsushita
Journal:  J Am Soc Nephrol       Date:  2020-06-23       Impact factor: 10.121

2.  Association of FGF23 with Incident Sepsis in Community-Dwelling Adults: A Cohort Study.

Authors:  Shejuti Paul; Suzanne E Judd; Henry E Wang; Orlando M Gutiérrez
Journal:  Kidney360       Date:  2020-07-29

Review 3.  Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

Authors:  Amarnath Marthi; Killian Donovan; Richard Haynes; David C Wheeler; Colin Baigent; Christopher M Rooney; Martin J Landray; Sharon M Moe; Jun Yang; Lisa Holland; Romina di Giuseppe; Annet Bouma-de Krijger; Borislava Mihaylova; William G Herrington
Journal:  J Am Soc Nephrol       Date:  2018-05-15       Impact factor: 10.121

4.  Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.

Authors:  Junichi Ishigami; Bernard G Jaar; Casey M Rebholz; Morgan E Grams; Erin D Michos; Myles Wolf; Csaba P Kovesdy; Shinichi Uchida; Josef Coresh; Pamela L Lutsey; Kunihiro Matsushita
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 5.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

6.  High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.

Authors:  Hirokazu Honda; Tetsuo Michihata; Kanji Shishido; Keiko Takahashi; Go Takahashi; Nozomu Hosaka; Misa Ikeda; Daisuke Sanada; Takanori Shibata
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

7.  Use of phosphate-binders and risk of infection-related and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort Study.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Masatomo Taniguchi; Hisako Yoshida; Hokuto Arase; Narihito Tatsumoto; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

Review 8.  Clinical epidemiology of infectious disease among patients with chronic kidney disease.

Authors:  Junichi Ishigami; Kunihiro Matsushita
Journal:  Clin Exp Nephrol       Date:  2018-09-03       Impact factor: 2.801

9.  Parathyroid hormone and premature thymus ageing in patients with chronic kidney disease.

Authors:  Kenichiro Iio; Daijiro Kabata; Rei Iio; Yosuke Imai; Masaki Hatanaka; Hiroki Omori; Yoshihiko Hoshida; Yukihiko Saeki; Ayumi Shintani; Takayuki Hamano; Yoshitaka Isaka; Yutaka Ando
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

10.  Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome.

Authors:  Mark R Hanudel; Matthew S Zinter; Lucia Chen; Kinisha Gala; Michelle Lim; Mona Guglielmo; Tanaya Deshmukh; Sitaram Vangala; Michael Matthay; Anil Sapru
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.